BARC Study Reveals Top Challenges to Becoming a Data-Driven Enterprise
Alation Inc., the leader in enterprise data catalogs, today announced the results of a global study, Leverage Your Data, A Data Strategy Checklist for the Journey to the Data-Driven Enterprise, which found that while nearly every company wants to be data-driven, the lack of documentation and knowledge about data inhibits that goal. The study, sponsored by Alation and carried out by Business Application Research Center (BARC), reveals that a key enabler to becoming a data-driven enterprise is the implementation of a successful data catalog that drives active contribution and collaboration from the business user.
According to the study, 90% of respondents indicate that data has a high priority in enterprise decision-making yet only 25% state that decisions are predominantly or purely made based on data. Several roadblocks inhibit the business user from embracing data and therefore prevent organizations from becoming data-driven. Participants report a lack of information and documentation on data, insight into who is using what data and for what purpose, and inconsistent meanings and interpretations of data as blockers. They also cite that data access is too complicated and that significant time is wasted asking the same questions about data or repeating work, further preventing business users from making data-driven decisions.
To overcome these obstacles, the report says that enterprises need to foster a data culture that empowers the business users. The data catalog drives data democratization by providing widespread access to data and encouraging a collaborative information exchange where data users – from business users to data analysts – can engage in an iterative process that ensures data quality and the proper use of data. The catalog tackles the challenges associated with data documentation by providing a business glossary that facilitates cross-departmental access to approved data definitions, ensuring that the meaning and interpretations of key figures in the organization are consistent. By removing these hurdles and empowering business users with a collaborative platform, organizations are able to unlock the true value of their data. This is why 77% of respondents currently use or are planning to use a data catalog.
“The BARC study mirrors the challenges our customers experienced prior to using Alation. Organizations need a data catalog that enables search and discovery, provides the context on how to use the data, and fosters collaboration among data users,” said Satyen Sangani, CEO and co-founder of Alation. “Alation is the foundation for building a data culture and we’re seeing more enterprises leverage our data catalog to drive that cultural shift and derive more value from their data.”
For four consecutive years, Alation has been named the top-ranked data catalog in Dresner Advisory Services’ 2020 Wisdom of Crowds® Data Catalog Market Study. Alation has also been recognized as a leader in the Forrester Wave for Machine Learning Data Catalogs, a three-time leader in Gartner’s Magic Quadrant for Metadata Management Solutions, and selected as a Gartner Peer Insights Customer’s Choice for Metadata Management Solutions.
To download a copy ofLeverage Your Data, a Data Strategy Checklist for the Journey to the Data-Driven Enterprise, click here.
To learn more about the study, register for the BARC Launch Party: How do Companies Find, Understand and use Trusted Data for Analytics? which is being held twice, once at 9am CEST and once at 5pm CEST on June 25, 2020.
Alation pioneered the data catalog market, leading the evolution of data management towards driving data culture. Alation customers leverage the data catalog as a platform for data search & discovery, data governance, data stewardship, analytics, and digital transformation. With its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation provides a platform to support a broad range of data intelligence solutions by combining machine learning with human insight to tackle the most demanding challenges in data management. Nearly 200 organizations are driving their data cultures and improving their organizations’ decision making with Alation, including AbbVie, DraftKings, Exelon, Finnair, Genentech, GoDaddy, Marks & Spencer, MercadoLibre, Munich Re, New Balance, New Relic, Pfizer, Scandinavian Airlines, Scout24 and US Foods. Headquartered in Silicon Valley, Alation is funded by Costanoa Ventures, Data Collective Venture Capital, Icon Ventures, Sapphire Ventures, and Salesforce Ventures. For more information, visit alation.com.
BARC (Business Application Research Center) is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence (BI) and analytics, enterprise content management (ECM) and customer relationship management (CRM). The company was founded in 1999 as a spin-off of the Chair of Business Administration and Information Systems at the Julius-Maximilians-University in Würzburg. Today, BARC combines empirical and theoretical research, technical expertise and practical experience, including a constant exchange with all market participants. For more information, visit: www.barc-research.com
Director, Public Relations, Alation
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen